Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Afecta Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Afecta Pharmaceuticals Inc. is using its pharmacogenetic platform to match complex forms of neurologic and psychiatric illnesses with the chemistry of candidate drugs that can be rapidly developed for treating the illnesses. Afecta intends to identify compounds to serve unmet clinical needs and to partner with others to bring targeted compounds to market at significantly lower R&D cost than de novo discovery.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel